• N Glynn, N Lynn, C Donagh, R K Crowley, D Smith, C J Thompson, A D K Hill, F Keeling, and A Agha.
• Division of Endocrinology, Beaumont Hospital, RCSI Medical School, Dublin 9, Ireland.
• Ir J Med Sci. 2011 Mar 1; 180 (1): 191-4.

BackgroundThere are conflicting data in the literature about the sensitivity of sestamibi scintigraphy in parathyroid tumour localisation in primary hyperparathyroidism (PHPT).AimWe aimed to evaluate the overall sensitivity of this modality in parathyroid tumour localisation and to determine clinical and biochemical factors which influence sensitivity of this method.MethodsWe performed a retrospective review of 57 patients with a biochemical diagnosis of PHPT who had sestamibi scintigraphy performed.ResultsThe sensitivity of sestamibi scanning was 56% in whole group and 63% in those without nodular thyroid disease. Among the patients with confirmed single gland disease (biochemical cure after surgical removal of a single adenoma), sensitivity was 71%. A positive scan was associated with younger age, greater adenoma weight and higher pre-operative serum calcium. Concordance between the sestamibi and neck ultrasonography was 92% accurate in pre-operative tumour localisation.ConclusionSestamibi scintigraphy was more likely to be positive in younger patients without nodular thyroid disease who have larger parathyroid adenomas with more severe hyperparathyroidism.

21 keywords...

hide…